Novartis Ag

Ksq Therapeutics, Inc.

Andrew Alistair Wylie

Michael Scott Visser

Michael R Schlabach

Vesselina Cooke

Xu Zhu

Padmaja Yerramilli-Rao

Jehrod Burnett Brenneman

Elsa Beyer Krall

The present disclosure relates to use of a protein kinase C (PKC) inhibitor in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, and related disclosure embodiments. The disclosure further relates to use of a pharmaceutical combination comprising a PKC inhibitor and another therapeutic agent, such as an MDM2 inhibitor, in the treatment or prevention of a proliferative disease.

Protein kinase C inhibitors for treatment of uveal melanoma

The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X, X, X, X, R, R, R, R, R, and Rare defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.

Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors

Growing community of inventors

Newton, MA, United States of America

Andrew Alistair Wylie